Healthcare Leaders Income ETF (HHL.TO) Buy,…

Home

Daily Stock Opinions and Ratings

Healthcare Leaders Income ETF (HHL.TO)

7.45

-0.02 (0.27%)

as of Aug 31, 2026, 7:59:56 pm Market Open.

232 watching

Investor Insights

Aug 31, 2026, 12:00 am

This summary was created by AI, based on 2 opinions in the last 12 months.

The Healthcare Leaders Income ETF (HHL-T) is currently navigating a challenging environment within the US healthcare sector, particularly influenced by negative sentiment towards health insurance companies. Despite this, the ETF has an interesting characteristic; its favorite holding, McKesson Corporation (MCK), is a drug distributor that does not directly manufacture products but plays a crucial role in the healthcare supply chain. The fund maintains an equal weight strategy with a diversified portfolio featuring approximately 20-23 large global healthcare names, including significant allocations to pharmaceuticals, healthcare equipment, and biotechnology. While the management expense ratio (MER) is around 1%, which some may consider on the pricier side, the ETF generates additional income through a covered-writing strategy. This element of diversification offers Canadian investors a strategic way to mitigate sector-specific risks in their portfolios.

Consensus

Neutral

Valuation

Fair Value

Similar

JNJ

DON'T BUY

The yield is extremely good. The problem is that there is not much movement on the upside. He prefer other things with upside potential. The Health Care sector is a good theme.

COMMENT

They find some of the best healthcare stocks and then write options to increase the returns. He likes what they are trying to do. The more volatility in the sector there is, the higher the option premium will be.

COMMENT

A yield of almost 9% and almost all a return of capital? There will be negative impacts on the US healthcare sector. The covered call strategy yields a return as a capital gain. He deferred the callers's question to the manager of the ETF. He thinks this is a good way to get yield in this sector if this is what you want.

DON'T BUY

Big marijuana components in the name. He thinks the mergers in the sector is going to be kind of a zero-sum game for the ETF. He would look into the individual names for potential targets in the smaller names.

COMMENT

No cannabis in this. It's 20 equal-weighted healthcare stocks, the biggest in the world, the mega-caps. Lately this has underperformed the S&P so beware as we head into a rate-sensitive market. It's more risky than your typical ETF.

BUY

Caller looking for a defensive holding. He loves what they are doing – an active approach to healthcare. They write covered calls and can generate capital gains. It should perform well in a downturn. Once we are at a low valuation and they are recovering you don’t want to be in this.

COMMENT

Popular. It has a covered call overlay so it's one of the more pricey ETFs at a 1.37% MER. They do quantitative screens on the healthcare companies they pick.

BUY

It is the healthcare leaders strategy ETF, actively managed with a covered call overlay. He sees a yield of about 9% but the holdings yield 3-4% so the rest is from the options strategy. The yield is sustainable if the managers know what they are doing. He likes the exposure and what they are trying to do.

DON'T BUY

Ignore this one. A recent arrival. Another covered call ETF. Compare it to ZUH or XLB, which are so much cheaper. If you like the healthcare sector, which he would question with the Trump wild card, be careful and pick a mainstream ETF.

DON'T BUY

Health care leaders. They use option strategies to enhance yield. As broad markets turned down in '15/16, this index fell and now that things have recovered, it has done so but less than the market. This is a way to play this space. It is an active strategy and a fine one if you want exposure to healthcare.

BUY

It's been building a base and current levels may rise past $9. He likes this, though it's in a volatile sector. HHL is acting quite well. He'd buy it now, and certainly when it breaks out past $9.

COMMENT

HHL-T vs ZUB: The performance of HHL has been mediocre since 2015. You're buying yield, but not getting growth. But there's nothing wrong with great yield. In ZUB, you get the opposite. Growth vs. yield: Which do you want?

HOLD

An aging population is good for this sector, but this sector is under scrutiny, too. Trump is getting tough on drug prices. That said, healthcare is a good place to be. He wouldn't add to an existing position. Hold no more than 5% in a sector.

BUY

Largely international healthcare companies with an option strategy overlaying it. It is an active strategy. It is a nice combination for exposure to the healthcare sector. It will be a good yielder but not a big grower.

WEAK BUY

He loves covered call strategies. They are very active managers and he thinks they do a very good job of it. The last few years have been an up market in the healthcare market. XLV-N is the broad US healthcare market. You have a much better return with HHL-T because of the dividend as well. It is a good way to hold healthcare late in the cycle.

Showing 61 to 75 of 89 entries

Most Recent Experts

Andrey Omelchak

LionGuard Capital Management

Jim Cramer - Mad Money

CNBC

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Healthcare Leaders Income ETF (HHL.TO)